CROI 2016 Program at a Glance

Program and Agenda

682 Longer-Term Renal Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate Bart J. Rijnders 1 ; Frank A. Post 2 ; Armin Rieger 3 ; EugenioTeofilo 4 ; DavidWohl 5 ; Paul E. Sax 6 ; Susan Guo 7 ; Andrew Cheng 7 ; Moupali Das 7 ; Marshall Fordyce 7 1 ErasmusUnivMedCntr,Rotterdam,Netherlands; 2 King’sCollHospNHS FndnTrust,London,UK; 3 MedUnivofVienna,Vienna,Austria; 4 Hosp dosCapuchos,CentroHospardeLisboaCentral,Lisbon,Portugal; 5 Univ ofNorthCarolinaatChapelHill,ChapelHill,NC,USA; 6 Brighamand Women’sHosp,HarvardMedSch,Boston,MA,USA; 7 GileadScis, Inc, FosterCity,CA,USA 683 Clinical Risk Factors for Severe Tenofovir (TDF) Associated Renal Tubulopathy 1 King’sCollLondon,London,UK; 2 UnivCollLondon,London,UK; 3 St Georges’HospNHSTrust,London,UK; 4 ImperialCollHlthcareNHSTrust, London,UK; 5 SouthTeesHospNHSFndnTrust,Middlesbrough,UK; 6 BrightonandSussexHospsNHSTrust,Brighton,UK; 7 RoyalFreeLondon NHSFndnTrust,London,UK; 8 ChelseaandWestminsterHospNHSFndn Trust,London,UK; 9 King’sCollHospNHSFndnTrust,London,UK 684 Short-Term Renal Impact of Tenofovir Among HIV- Infected Patients in North America 1 JohnsHopkinsBloombergSchofPH,Baltimore,MD,USA; 2 Johns HopkinsUniv,Baltimore,MD,USA; 3 JohnsHopkinsUnivSchofMed, Baltimore,MD,USA; 4 UnivofCaliforniaSanFrancisco,SanFrancisco,CA, USA; 5 BritishColumbiaCntr forExcellence inHIV/AIDS,Vancouver,BC, Canada; 6 Mid-AtlanticPermanenteMedGroup,Rockville,MD,USA; 7 Univ ofWashington,Seattle,WA,USA; 8 UnivCentraldelCaribe,Bayamon,PR, USA; 9 UnivofNorthCarolinaatChapelHill,ChapelHill,NC,USA 685 Associations of Tenofovir Disoproxil FumarateWith Urine Biomarkers of Kidney Damage Lisa Hamzah 1 ; Sophie Jose 2 ; Aseel Hegazi 3 ; Angela Bailey 4 ; David Chadwick 5 ; DeborahWilliams 6 ; Margaret Johnson 7 ; Rachael Jones 8 ; Caroline Sabin 2 ; Frank A. Post 9 RuibinWang 1 ; Gregory M. Lucas 2 ; Michelle Estrella 3 ; Michael Shlipak 4 ; Marianne Harris 5 ; Michael A. Horberg 6 ; Mari M. Kitahata 7 ; Angel M. Mayor 8 ; Sonia Napravnik 9 ; Alison Abraham 1 Vasantha Jotwani 1 ; Rebecca Scherzer 1 ; Michelle Estrella 2 ; Lisa Jacobson 3 ; MalloryWitt 4 ; Frank J. Palella 5 ; Bernard J. Macatangay 6 ; Chirag Parikh 7 ; Joachim Ix 8 ; Michael Shlipak 1 1 UnivofCaliforniaSanFrancisco,SanFrancisco,CA,USA; 2 JohnsHopkins UnivSchofMed,Baltimore,MD,USA; 3 JohnsHopkinsUniv,Baltimore, MD,USA; 4 Harbor-UnivofCaliforniaLosAngelesMedCntr,Torrance,CA, USA; 5 NorthwesternUniv,Chicago, IL,USA; 6 UnivofPittsburghSchof Med,Pittsburgh,PA,USA; 7 YaleUnivSchofMed,NewHaven,CT,USA; 8 UnivofCaliforniaSanDiego,SanDiego,CA,USA

Session P-Q2 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM Renal and Bone Disease: Risk Factors and Biomarkers 686 Nature of Immunosuppression and Chronic Kidney Disease Risk in HIV-Positive Persons Lene Ryom 1 ; Jens D. Lundgren 1 ; Peter Reiss 2 ; Michael Ross 3 ; Christoph A. Fux 4 ; Philippe Morlat 5 ; Eric Fontas 6 ; Colette Smith 7 ; Amanda Mocroft 7 ; for the D:A:D Study Group 1 RigsHospet,UnivofCopenhagen,Copenhagen,Denmark; 2 Amsterdam Inst forGlobalHlthandDevelop,Amsterdam,Netherlands; 3 Mount SinaiSchofMed,NewYork,NY,USA; 4 KantonsspitalAarau,Aarau, Switzerland; 5 UnivdeBordeaux,Bordeaux,France; 6 NiceUnivHosp,Nice, France; 7 UnivCollLondon,London,UK 687 Traditional and Viral Factors AssociatedWith Iohexol- Based GFR Slope Over 3 Years Gregory M. Lucas 1 ; Mohamed G. Atta 1 ; Katie Zook 1 ; Allison M. McFall 1 ; Shruti H. Mehta 1 ; Derek M. Fine 1 ; James H. Stein 2 ; George J. Schwartz 3 1 JohnsHopkinsUniv,Baltimore,MD,USA; 2 UnivofWisconsin-Madison, Madison,WI,USA; 3 UnivofRochester,Rochester,NY,USA 688 The Racial Survival Paradox in HIV+ End-Stage Renal Disease (ESRD) Patients Keri N. Althoff 1 ; Michelle Estrella 2 ; Alison Abraham 1 ; John Gill 3 ; Mari M. Kitahata 4 ; Michael A. Horberg 5 ; MarkW. Hull 6 ; Angel M. Mayor 7 ; Frank J. Palella 8 ; Gregory M. Lucas 9 1 JohnsHopkinsBloombergSchofPH,Baltimore,MD,USA; 2 Johns HopkinsUnivSchofMed,Baltimore,MD,USA; 3 UnivofCalgary,Calgary, AB,Canada; 4 UnivofWashington,Seattle,WA,USA; 5 Mid-Atlantic PermanenteMedGroup,Rockville,MD,USA; 6 BCCntr forExcellence in HIV/AIDS,Vancouver,BC,Canada; 7 UnivCentraldelCaribe,Bayamon, PR,USA; 8 NorthwesternUniv,Chicago, IL,USA; 9 JohnsHopkinsUniv, Baltimore,MD,USA 689 Activation and Senescence Markers in HIV Patients With Chronic Kidney Disease Alexandra Ozanne 1 ; Frédéric-Antoin Dauchy 2 ; Claire Rigothier 2 ; Cécile Le Scanf-Terrien 2 ; Pierre Duffau 2 ; Estibaliz Lazaro 2 ; Charles Cazanave 3 ; Sylvie Lawson-Ayayi 4 ; LindaWittkop 2 ; Isabelle Pellegrin 2 1 UnivdeBordeaux,Bordeaux,France; 2 CHUdeBordeaux,Bordeaux, France; 3 CHUdeBordeaux,BordeauxCedex,France; 4 INSERM, ISPED, INSERMU897,Bordeaux,France 690 Soluble CD163 Predicts Incident Chronic Lung and Kidney Disease in HIV-1 Infection Ditte M. Kirkegaard-Klitbo 1 ; Niels Mejer 2 ;Troels Bygum Knudsen 3 ; Holger J. Møller 4 ; Søren K. Moestrup 4 ; Susanne D. Nielsen 1 ; Gitte Kronborg 2 ;Thomas Benfield 2

Poster Listings

1 RigsHospet,UnivofCopenhagen,Copenhagen,Denmark; 2 Hvidovre Hosp,UnivofCopenhagen,Hvidovre,Denmark; 3 HillerødHosp,Univ ofCopenhagen,Hillerød,Denmark; 4 AarhusUnivHosp,AarhusNord, Denmark

67

CROI 2016